Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > Chuikyo on FY2024 Reimbursement Reform
Chuikyo on FY2024 Reimbursement Reform
-
Revisit 25-Plus-Year Listing Requirement for Essential Drugs: Chuikyo Members
November 13, 2023
-
MHLW Proposes New Premium with Easier-than-Sakigake Requirements to Fight Lag, Loss
November 13, 2023
-
Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
-
No Objections to Reflecting Company Indices for Generic Supplies in Pricing: Chuikyo
October 30, 2023
-
Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
October 23, 2023
-
Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
-
Many Back Expansion in Range of CEA Price Tweaks for Pricey Drugs: Chuikyo
October 5, 2023
-
Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
-
Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
-
Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
-
JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
-
Chuikyo Mixed on Expanding Range of CEA Price Adjustments for Pricey Meds
September 14, 2023
-
Industry Requests Rewards for SaMDs that Help Doctors’ Workstyle Reform
September 1, 2023
-
Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
-
Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
-
Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
August 24, 2023
-
With Generics Now in Common Use, It’s Time for Debate on LLP Copay: Payers
August 4, 2023
-
Payers Want Phase-Out of Medical Fee Premiums for Generic Use; HCPs Eye Change in Entry Pricing
August 3, 2023
-
Chuikyo OKs Plan to Move Back Medical Fee Revisions to June from FY2024; Drug Price Updates to Remain in April
August 3, 2023
-
Industry Calls for Excluding Orphan Drugs from Cost-Effectiveness Assessment
August 3, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…